MICHAEL B. JACOBS, M.D.
Calcium entry blockers or calcium antagonists are being used for a growing number of cardiovascular problems (1). Because diltiazem (Cardizem; Marion Laboratories, Kansas City, Missouri), a recent addition to this group, offers certain advantages over the other currently available calcium antagonists (nifedipine and verapamil), it can be expected to be prescribed with increasing frequency (2). We report a previously unreported adverse effect of diltiazem, akathisia.
A 62-year-old man with several medical problems was admitted to the Stanford Medical Service on 13 January 1983. For the previous 15 years he had had poorly controlled hypertension, adult onset (type II) diabetes mellitus,
MICHAEL B. JACOBS. Diltiazem and Akathisia. Ann Intern Med. 1983;99:794–795. doi: 10.7326/0003-4819-99-6-794
Download citation file:
Published: Ann Intern Med. 1983;99(6):794-795.
Cardiology, Coronary Risk Factors, Hypertension, Nephrology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use